289 related articles for article (PubMed ID: 30587980)
1. Antiviral efficacy of nanoparticulate vacuolar ATPase inhibitors against influenza virus infection.
Hu CJ; Chen YT; Fang ZS; Chang WS; Chen HW
Int J Nanomedicine; 2018; 13():8579-8593. PubMed ID: 30587980
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory and combinatorial effect of diphyllin, a v-ATPase blocker, on influenza viruses.
Chen HW; Cheng JX; Liu MT; King K; Peng JY; Zhang XQ; Wang CH; Shresta S; Schooley RT; Liu YT
Antiviral Res; 2013 Sep; 99(3):371-82. PubMed ID: 23820269
[TBL] [Abstract][Full Text] [Related]
3. The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections.
Müller KH; Kainov DE; El Bakkouri K; Saelens X; De Brabander JK; Kittel C; Samm E; Muller CP
Br J Pharmacol; 2011 Sep; 164(2):344-57. PubMed ID: 21418188
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticulate vacuolar ATPase blocker exhibits potent host-targeted antiviral activity against feline coronavirus.
Hu CJ; Chang WS; Fang ZS; Chen YT; Wang WL; Tsai HH; Chueh LL; Takano T; Hohdatsu T; Chen HW
Sci Rep; 2017 Oct; 7(1):13043. PubMed ID: 29026122
[TBL] [Abstract][Full Text] [Related]
5. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption.
Sørensen MG; Henriksen K; Neutzsky-Wulff AV; Dziegiel MH; Karsdal MA
J Bone Miner Res; 2007 Oct; 22(10):1640-8. PubMed ID: 17576165
[TBL] [Abstract][Full Text] [Related]
6. Diphyllin Shows a Broad-Spectrum Antiviral Activity against Multiple Medically Important Enveloped RNA and DNA Viruses.
Štefánik M; Bhosale DS; Haviernik J; Straková P; Fojtíková M; Dufková L; Huvarová I; Salát J; Bartáček J; Svoboda J; Sedlák M; Růžek D; Miller AD; Eyer L
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215947
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic Prioritization of Diphyllin Derivatives That Block Filoviral Cell Entry by Vacuolar (H
Lindstrom A; Anantpadma M; Baker L; Raghavendra NM; Davey R; Davisson VJ
ChemMedChem; 2018 Dec; 13(24):2664-2676. PubMed ID: 30335906
[TBL] [Abstract][Full Text] [Related]
8. Nanoformulation of the Broad-Spectrum Hydrophobic Antiviral Vacuolar ATPase Inhibitor Diphyllin in Human Recombinant
Vojnikova M; Sukupova M; Stefanik M; Strakova P; Haviernik J; Kapolkova K; Gruberova E; Raskova K; Michalkova H; Svec P; Kudlickova MP; Huvarova I; Ruzek D; Salat J; Pekarik V; Eyer L; Heger Z
Int J Nanomedicine; 2024; 19():3907-3917. PubMed ID: 38708183
[TBL] [Abstract][Full Text] [Related]
9. Receptor tyrosine kinase inhibitors that block replication of influenza a and other viruses.
Kumar N; Sharma NR; Ly H; Parslow TG; Liang Y
Antimicrob Agents Chemother; 2011 Dec; 55(12):5553-9. PubMed ID: 21930873
[TBL] [Abstract][Full Text] [Related]
10. Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models.
Fukao K; Ando Y; Noshi T; Kitano M; Noda T; Kawai M; Yoshida R; Sato A; Shishido T; Naito A
PLoS One; 2019; 14(5):e0217307. PubMed ID: 31107922
[TBL] [Abstract][Full Text] [Related]
11. Effects of diphyllin as a novel V-ATPase inhibitor on gastric adenocarcinoma.
Shen W; Zou X; Chen M; Liu P; Shen Y; Huang S; Guo H; Zhang L
Eur J Pharmacol; 2011 Sep; 667(1-3):330-8. PubMed ID: 21645513
[TBL] [Abstract][Full Text] [Related]
12. 2, 4, 5-Trideoxyhexopyranosides derivatives of diphyllin: Synthesis and anticancer activity.
Cai R; Li Y; Zhu L; Wei C; Bao X; Zhao Y
Chem Biol Drug Des; 2022 Aug; 100(2):256-266. PubMed ID: 35614538
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, Cytotoxicity, Anti-Migration and Anti-Invasion Activity of Diphyllin Heterocyclic Derivatives.
Shen W; Chen H; Wu M; Zhang T; Zhu L; Zhao Y
Med Chem; 2022; 18(1):122-129. PubMed ID: 33349219
[TBL] [Abstract][Full Text] [Related]
14. From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs?
Cheng CK; Tsai CH; Shie JJ; Fang JM
Future Med Chem; 2014 May; 6(7):757-74. PubMed ID: 24941871
[TBL] [Abstract][Full Text] [Related]
15. Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures.
Pizzorno A; Terrier O; Nicolas de Lamballerie C; Julien T; Padey B; Traversier A; Roche M; Hamelin ME; Rhéaume C; Croze S; Escuret V; Poissy J; Lina B; Legras-Lachuer C; Textoris J; Boivin G; Rosa-Calatrava M
Front Immunol; 2019; 10():60. PubMed ID: 30761132
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and identification of cytotoxic diphyllin glycosides as vacuolar H(+)-ATPase inhibitors.
Zhang Z; Ma J; Zhu L; Zhao Y
Eur J Med Chem; 2014 Jul; 82():466-71. PubMed ID: 24929344
[TBL] [Abstract][Full Text] [Related]
17. Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses.
Haasbach E; Pauli EK; Spranger R; Mitzner D; Schubert U; Kircheis R; Planz O
Antiviral Res; 2011 Sep; 91(3):304-13. PubMed ID: 21777621
[TBL] [Abstract][Full Text] [Related]
18.
Lloren KKS; Kwon JJ; Choi WS; Jeong JH; Ahn SJ; Choi YK; Baek YH; Song MS
J Virol; 2019 Mar; 93(6):. PubMed ID: 30602610
[TBL] [Abstract][Full Text] [Related]
19. Requirement for vacuolar proton-ATPase activity during entry of influenza virus into cells.
Guinea R; Carrasco L
J Virol; 1995 Apr; 69(4):2306-12. PubMed ID: 7884876
[TBL] [Abstract][Full Text] [Related]
20. ZT-25, a new vacuolar H(+)-ATPase inhibitor, induces apoptosis and protective autophagy through ROS generation in HepG2 cells.
Lu Y; Zhang R; Liu S; Zhao Y; Gao J; Zhu L
Eur J Pharmacol; 2016 Jan; 771():130-8. PubMed ID: 26689625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
